Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system-Reference-Cited by-同舟云学术

Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system

Published:2022-10 Issue: Volume:14 Page:100329
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Arruda Gustavo Viani,Lourenção Marina^ORCID,de Oliveira Jorge Henrique Caldeira,Galendi Julia Simões Correa,Jacinto Alexandre Arthur

Funder

Varian Medical Systems Inc

Publisher

Elsevier BV

Reference38 articles.

1. Lung cancer;Thai;Lancet North Am Ed,2021

2. Câncer de pulmão no Brasil;Araujo;J bras pneumol,2018

3. A decade of never-smokers among lung cancer patients—increasing trend and improved survival;Toh;Clin Lung Cancer,2018

4. Surgical treatment for early stage non-small cell lung cancer;Raman;J Thorac Dis,2018

5. Stereotactic body radiotherapy versus delayed surgery for early-stage non-small-cell lung cancer;Mayne;Ann Surg,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-20

2. Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system;BMC Health Services Research;2023-06-08

3. Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review;Oncology Research and Treatment;2022-12-12

4. The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer;The Lancet Regional Health - Americas;2022-10